I spoke to Dr. Regan today at length about Dascor and other issues. He's already done several cases with good EARLY results. The device is in the pilot phase that only includes 20 patients. There are a few slots left, but there is no way to tell how long they will be available.
We discussed many of the issues related to nucleus replacements and past failures. There is much about the Dascor design that addresses many of these issues. The stringent protocol for the pilot phase is interesting and it will be more interesting to see how the pivotal study will be designed.
More later.
Mark
|